LDN PHARMA LIMITED

Company Registration Number:
09400979 (England and Wales)

Unaudited abridged accounts for the year ended 30 June 2024

Period of accounts

Start date: 01 July 2023

End date: 30 June 2024

LDN PHARMA LIMITED

Contents of the Financial Statements

for the Period Ended 30 June 2024

Balance sheet
Notes

LDN PHARMA LIMITED

Balance sheet

As at 30 June 2024


Notes

2024

2023


£

£
Called up share capital not paid: 0 0
Fixed assets
Intangible assets: 3 5,734,465 5,001,621
Tangible assets:   0 0
Investments:   0 0
Total fixed assets: 5,734,465 5,001,621
Current assets
Stocks: 0 0
Debtors: 4 65,664 71,341
Cash at bank and in hand: 741 50,877
Investments:   0 0
Total current assets: 66,405 122,218
Creditors: amounts falling due within one year: 5 (366,542) (138,487)
Net current assets (liabilities): (300,137) (16,269)
Total assets less current liabilities: 5,434,328 4,985,352
Creditors: amounts falling due after more than one year:   (195,000) (366,710)
Provision for liabilities: 0 0
Total net assets (liabilities): 5,239,328 4,618,642
Capital and reserves
Called up share capital: 24,801 24,686
Share premium account: 5,614,888 4,864,773
Revaluation reserve: 00
Other reserves: 0 0
Profit and loss account: (400,361) (270,817)
Shareholders funds: 5,239,328 4,618,642

The notes form part of these financial statements

LDN PHARMA LIMITED

Balance sheet statements

For the year ending 30 June 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 27 March 2025
and signed on behalf of the board by:

Name: Ian Thompson
Status: Director

The notes form part of these financial statements

LDN PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2024

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

LDN PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2024

2. Employees

2024 2023
Average number of employees during the period 0 0

LDN PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2024

3. Intangible Assets

Total
Cost £
At 01 July 2023 5,001,621
Additions 732,844
Disposals 0
Revaluations 0
Transfers 0
At 30 June 2024 5,734,465
Amortisation
At 01 July 2023 0
Charge for year 0
On disposals 0
Other adjustments 0
At 30 June 2024 0
Net book value
At 30 June 2024 5,734,465
At 30 June 2023 5,001,621

LDN PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2024

4. Debtors

2024 2023
££
Debtors due after more than one year: 65,664 71,341

LDN PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2024

5. Creditors: amounts falling due within one year note

Trade creditors 162698 0 Accruals 156732 3375 Directors loan 47112 70112 Other creditors 0 65000

LDN PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2024

6. Related party transactions

Name of the related party: Paul Sweeney
Relationship:
Director
Description of the Transaction: Cash loan
£
Balance at 01 July 2023 8,654
Balance at 30 June 2024 8,654
Name of the related party: Ian Thompson
Relationship:
Director
Description of the Transaction: Cash Loan
£
Balance at 01 July 2023 61,458
Balance at 30 June 2024 38,458